Back to News
Market Impact: 0.4
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
Source: zacks.com
Healthcare & BiotechCompany FundamentalsProduct Launches
Novo Nordisk's CagriSema delivered greater weight loss than Eli Lilly's tirzepatide in type 2 diabetes and achieved 21% weight loss in obesity. The results strengthen Novo Nordisk's late-stage obesity and diabetes pipeline and could improve its competitive positioning in the GLP-1 treatment market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
LLY-0.45
More News
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Our top 10 things to watch in the stock market Friday
- Why is Hims & Hers Health stock rallying today?
- Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence
- Here's a rapid-fire update on all 31 of our stocks, including 2 to buy now
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production